Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Combination therapy shows promise for treating triple-negative breast cancer

Researchers at Baylor College of Medicine and collaborating institutions have identified a combination therapy for treating triple-negative breast cancer (TNBC) that results in durable tumor regression in an animal model of the condition.

27 Apr 2022

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

26 Apr 2022

The impact of leronlimab on CCR5 surface cell levels during long COVID

The researchers assessed the impact of long COVID-19 on C-C chemokine receptor-5 (CCR5) and immunosuppression.

26 Apr 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

25 Apr 2022

Monoclonal-antibody combination AZD7442 prevents COVID-19

In a recent study published in The New England Journal of Medicine, the researchers examined the monoclonal-antibody combination AZD7442 to prevent coronavirus disease 2019 (COVID-19).

25 Apr 2022

An abnormally suppressed immune system may be to blame in some cases of long COVID-19

A UCLA-led team of researchers studying the effect of the monoclonal antibody Leronlimab on long COVID-19 may have found a surprising clue to the baffling syndrome, one that contradicts their initial hypothesis.

22 Apr 2022

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.

21 Apr 2022

Investigating the impact of SARS-CoV-2 Omicron spike mutations

Researchers investigated the impact of amino acid substitutions of SARS-CoV-2 Omicron on spike protein function, processing, and neutralization susceptibility.

20 Apr 2022

New, longest documented case of persistent acute SARS-CoV-2 infection

Researchers describe a 16-month-old case of SARS-CoV-2 infection in an immunocompromised individual.

18 Apr 2022

How the test-to-treat pillar of the US covid strategy is failing patients

The federal "test-to-treat" program, announced in March, is meant to reduce covid hospitalizations and deaths by quickly getting antiviral pills to people who test positive. But even as cases rise again, many Americans don't have access to the program.

15 Apr 2022

Comparison of neutralizing antibody response following SARS-CoV-2 booster vaccination with breakthrough infection

A new study examined the serological immune responses and antibody-dependent cell-mediated phagocytosis in individuals who had either received two doses of a standard vaccine regime, a booster dose following the regime, or a breakthrough infection following vaccination.

15 Apr 2022

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers demonstrated the evolution of multi-system inflammatory syndrome in children (MIS-C) following acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

12 Apr 2022

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

They might look like cells and act like cells. But a new potential COVID-19 treatment is actually a cleverly disguised trickster, which attracts viruses and binds them, rendering them inactive.

12 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers tested the efficacy of sotrovimab in non-hospitalized patients with SARS-CoV-2 infection.

7 Apr 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022

Study says duplilumab reduces mortality from COVID-19

A recent report posted to the medRxiv* preprint server assessed the efficacy of dupilumab in blocking the IL-13 signaling pathway and its efficacy in reducing the COVID-19 associated mortality.

5 Apr 2022